Helena W. Rodbard, MD; Paul S. Jellinger, MD
Potential Conflicts of Interest: Dr. Rodbard: Consultancy: Novo Nordisk, Amylin, Novartis, Merck; Payment for lectures including service on speakers bureaus: Amylin, Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Sanofi. Dr. Jellinger: Consultancy: Amylin, Merck, Novo Nordisk; Payment for lectures including service on speakers bureaus: Amylin, Merck, Novo Nordisk, Boehringer-Ingleheim.
Rodbard HW, Jellinger PS. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus. Ann Intern Med. 2012;157:75–76. doi: 10.7326/0003-4819-157-1-201207030-00017
Download citation file:
© 2018
Published: Ann Intern Med. 2012;157(1):75-76.
DOI: 10.7326/0003-4819-157-1-201207030-00017